0000899140-24-001036.txt : 20240920 0000899140-24-001036.hdr.sgml : 20240920 20240920162016 ACCESSION NUMBER: 0000899140-24-001036 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240918 FILED AS OF DATE: 20240920 DATE AS OF CHANGE: 20240920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DONG-A ST CO., LTD CENTRAL INDEX KEY: 0001799260 ORGANIZATION NAME: STATE OF INCORPORATION: M5 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37809 FILM NUMBER: 241313640 BUSINESS ADDRESS: STREET 1: 64, CHEONHO-DAERO STREET 2: DONGDAEMUN-GU CITY: SEOUL STATE: M5 ZIP: 02587 BUSINESS PHONE: 82-2-920-8184 MAIL ADDRESS: STREET 1: 64, CHEONHO-DAERO STREET 2: DONGDAEMUN-GU CITY: SEOUL STATE: M5 ZIP: 02587 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroBo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001638287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472389984 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 CONCORD AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: (857) 702-9600 MAIL ADDRESS: STREET 1: 545 CONCORD AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: Gemphire Therapeutics Inc. DATE OF NAME CHANGE: 20150331 4 1 form4.xml X0508 4 2024-09-18 0001638287 NeuroBo Pharmaceuticals, Inc. NRBO 0001799260 DONG-A ST CO., LTD 64, CHEONHO-DAERO DONGDAEMUN-GU SEOUL M5 02587 KOREA, REPUBLIC OF true false Common Stock 2024-09-12 2024-09-12 4 S 0 407 3.75 D 5347792 D Warrants to Purchase Common Stock 3.93 2024-09-18 4 P 0 2544530 A 2024-09-18 2025-09-18 Common Stock 2544530 2544530 D Warrants to Purchase Common Stock 3.93 2024-09-18 4 P 0 3816795 A 2024-09-18 2029-09-18 Common Stock 3816795 3816795 D Reporting Person's sale of 407 shares of Common Stock at a price per share of $3.75 occurred on September 12, 2024. On June 13, 2024, the Issuer issued (i) Series A Warrants to purchase up to an aggregate of 2,544,530 shares of the Issuer's common stock (the "Series A Warrant Shares") and (ii) 3,816,795 Series B Warrants to purchase up to an aggregate of 3,816,795 shares of the Issuer's common stock (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants"), to the reporting person pursuant to a securities purchase agreement dated the same date (the "Purchase Agreement"), in connection with a private placement of securities by the Issuer to certain investors. The issuance of the Warrants under the Purchase Agreement was subject to stockholder approval under applicable NASDAQ rules, which was obtained at a special meeting of the Issuer's stockholders held on September 18, 2024. These warrants expire on the earlier of (i) the twelve months anniversary of September 18, 2024, and (ii) the 60th day following the date on which the Issuer publicly announce the receiving of positive Phase 1 MAD data readout for DA-1726. These warrants expire on the earlier of (i) the five years anniversary of September 18, 2024 and (ii) the six months anniversary following the date on which the Issuer publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726. Dong-A St Co., Ltd.; By: /s/ Jae Hun Jung, Chief Executive Officer 2024-09-20